<DOC>
	<DOCNO>NCT01715987</DOCNO>
	<brief_summary>Nucleotide anti-viral analogue , include adefovir TDF , demonstrate kidney toxicity HIV/HBV co-infected patient HBV mono-infected European patient . Investigators suspect similar kidney proximal tubular injury also occur HBV mono infect Asian patient receive TDF treatment .</brief_summary>
	<brief_title>Tubular Function Asian-American Patients Receiving TDF ETV HBV Treatment</brief_title>
	<detailed_description>The primary objective study evaluate safety use ETV TDF least 144 week treatment term effect renal tubular function determine ( 1 ) 24 hour Urine phosphate ( waste &gt; 1200 mg daily ) ; ( 2 ) 24 hour β2-microglobulinuria ( NL β2-microglobulin level , &lt; 1 mg daily ) ; ( 3 ) fractional excretion uric acid , ( 4 ) fractional tubular reabsorption phosphorus . The secondary objective evaluate : 1 . To evaluate compare anti-viral effect TDF ETV determine percentage patient achieve HBV DNA level 60 IU/mL ( quantitative HBV DNA PCR test low level detection 60 IU/mL ) ALT normalization routine biochemical test 144 week treatment . 2 . Serological response include percentage patient HBeAg loss seroconversion HBsAg loss seroconversion TDF ETV treatment Asian-American adult CHB infection . 3 . To evaluate three-year ( one year treatment enrollment two year treatment enrollment ) percentage patient anti-HBV drug resistance TDF ETV , include genotypic mutation Asian-American adult CHB .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1870 yearold AsianAmerican male female patient HBeAg+ HBeAgCHB On TDF ETV monotherapy 1224 month , previously expose oral HBV drug , receive type interferon treatment past 12 month Be willing participate Continuation HBV treatment medically indicate . That HBeAgpositive subject , HBeAg remain positive HBeAg becomes negative still detectable DNA PCR method ; HBeAgnegative subject , HBV DNA either detectable undetectable PCR method No clinical virologic evidence antiHBV resistance TDF treatment time enter test Serum creatinine &lt; 1.5 mg/L estimate glomerular filtration rate ( creatinine clearance ) ≥ 60 mL/min/1.73m2 CockcroftGault equation : ( 140age year ) ( body weight [ kg ] ) / ( ( 72 ) ( serum creatinine [ mg/dl ] ) ) [ Note : multiply estimate rate 0. 85 woman ; use actual body weight ] Adequate hematologic function ( absolute neutrophil count ≥ 1,500/mm3 ; hemoglobin ≥ 10.0 g/dL ) To assure subject regularly follow per study protocol minimize drop rate , subject document pretreatment full evaluation necessary blood test , medical adherence HBV treatment , regular followup ( i.e. , HBV treatment miss HBV medication ( TDF ETV ) week , medical followup HBV treatment least every 6 month necessary lab perform . In absence exclusion criterion . Ethnicity : NonAsian CHB patient Age : &gt; 70 year old Body weight height : BMI ≥ 30 Concomitant nephrotoxic agent record prescription nonprescription item include herbs natural remedy , NSAIDs , acyclovir , statin , ACEI ARBs , Valproate Any antiretroviral med , antibiotic exposure study note History HCV , HDV , HIV coinfection Prior history clinical hepatic decompensation define direct ( conjugate ) bilirubin ≥ 1.2 ULN ; PT ≥ 1.2 ULN , platelets ≤ 50,000/mm3 , serum albumin ≤ 3.5 g/dL , ascites , jaundice , encephalopathy , variceal hemorrhage Serum αfetoprotein ≥ 50 ng/mL Evidence hepatocellular carcinoma ( HCC ) History solid organ bone marrow transplantation History malignancy past 5 year Pregnant woman , woman breast feed believe may wish become pregnant course study . Males females reproductive potential willing use effective method contraception study . For male , condom use female , barrier contraception method use combination one form contraception . History significant renal disease History significant bone disease History HTN DM medical treatment Ongoing therapy follow : 1 . Nephrotoxic agent 2 . Parenteral aminoglycoside antibiotic 3 . Cidofovir 4 . Cisplatin 5 . Foscarnet 6 . IV amphotericin B 7 . IV pentamidine 8 . Oral IV ganciclovir 9 . Cyclosporine 10 . Tacrolimus 11 . IV vancomycin 12 . Chronic daily nonsteroidal antiinflammatory drug therapy 13 . Competitors renal excretion Systemic chemotherapeutic agent 14 . Systemic corticosteroid 15 . Interleukin2 ( IL2 ) immunomodulating agent Investigational agent ( except express approval lead investigator ) Administration medication must discontinue least 30 day prior Baseline Visit duration study period . 1 . Known hypersensitivity study drug , metabolite formulation excipients 2 . Any condition ( include alcohol substance abuse ) prior therapy , opinion Investigators , would make subject unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Tubular dysfunction</keyword>
	<keyword>Entecavir</keyword>
	<keyword>Tenofovir</keyword>
</DOC>